CJC-1295: Understanding This Growth Hormone Releasing Hormone Analog

Natural GHRH lasts minutes in your bloodstream. CJC-1295 lasts days. That's the whole point.

What Is CJC-1295?

CJC-1295 is a synthetic peptide that mimics GHRH - growth hormone releasing hormone. Your body makes natural GHRH, but it has a fatal flaw: it degrades in minutes.

CJC-1295 was engineered to last longer. Much longer.

The peptide exists in two forms:

• CJC-1295 with DAC (Drug Affinity Complex): This version binds to albumin in your blood, extending its half-life to 6-8 days. Less frequent injections. More sustained GH elevation.
• CJC-1295 without DAC (also called Modified GRF 1-29): No albumin binding. Half-life drops to about 30 minutes. Often paired with ipamorelin for synergistic effects and pulsatile GH release that mimics natural patterns.

Both are 30-amino-acid sequences derived from the first 29 amino acids of GHRH. Strategic substitutions make them resistant to enzymatic breakdown. Research in the Journal of Clinical Endocrinology & Metabolism has explored how these modifications affect GH secretion patterns and pharmacokinetics.

How Does CJC-1295 Work?

CJC-1295 binds to GHRH receptors on somatotroph cells in your anterior pituitary gland. When those receptors activate, they trigger intracellular signaling that leads to growth hormone synthesis and secretion.

Simple enough. But here's the key difference from natural GHRH:

Natural GHRH gets destroyed by an enzyme called dipeptidyl peptidase-IV (DPP-IV). Fast. CJC-1295's amino acid substitutions make it resistant to DPP-IV. The result? Prolonged receptor activation. Sustained GH release.

Animal studies show that CJC-1295 with DAC can maintain elevated GH and IGF-1 levels for extended periods after a single injection.

This sustained elevation differs from the pulsatile pattern of natural GH secretion. The no-DAC variant, by contrast, produces shorter GH pulses that more closely approximate natural rhythms, which is one reason it is often preferred in research and clinical contexts.

What Is CJC-1295 Studied For?

CJC-1295 isn't FDA-approved. But research has explored potential applications:

• Growth hormone support: Studies have examined CJC-1295's effects on GH and IGF-1 levels in adults with age-related decline.
• Body composition: Research has explored sustained GH elevation and its relationship to lean muscle mass and fat distribution.
• Sleep quality: Because GH plays a role in sleep architecture, GHRH analogs have been studied for their effects on sleep depth and overnight recovery.
• Recovery and tissue repair: GH supports collagen synthesis and tissue regeneration, and CJC-1295 has drawn research interest in the context of recovery from training and injury.

CJC-1295 and ipamorelin combination: In practice, CJC-1295 (especially the no-DAC variant) is often stacked with ipamorelin.

Why? Different mechanisms. CJC-1295 works through GHRH receptors. Ipamorelin works through ghrelin receptors. Hit both pathways, get more robust and physiologically appropriate GH pulses than either peptide alone.

Larger clinical trials would help further characterize this combination's effects.

CJC-1295 Regulatory Status

The FDA's 503A Bulk Substances List determines which peptides can be legally compounded by state-licensed pharmacies. CJC-1295 is Category 2 - which means it doesn't meet safety and quality criteria for compounding under 503A regulations.

Category 2 reflects concerns about insufficient data on safety, efficacy, or physicochemical characteristics. It doesn't mean the peptide is inherently dangerous. It means more evidence is needed.

The FDA reviews these categories periodically. Reclassification happens as new data emerges.

What this means: CJC-1295 is not legally available through compliant U.S. compounding pharmacies operating under 503A.

Products from research chemical suppliers or international vendors carry significant risks - contamination, inaccurate dosing, and no sterility testing among them.

The FDA 503A Bulk Substances List is updated periodically, and stakeholders can submit nominations for substances to move from Category 2 to Category 1. PeptidePrescript only works with Category 1 peptides compounded by accredited 503A pharmacies, and monitors FDA guidance for status changes.

Side Effects and Safety

Safety information for CJC-1295 comes primarily from clinical research and reported observations. Reported effects studied across the literature include:

• Injection site reactions: Redness, swelling, or discomfort, common with subcutaneous peptide administration
• Water retention: Elevated GH can produce temporary fluid retention
• Headaches: Reported in some studies, particularly with higher exposures
• Flushing or transient lightheadedness: Most commonly associated with the no-DAC variant
• Effects on glucose metabolism: Because GH affects insulin sensitivity, blood glucose can shift in some individuals and is monitored as part of medical supervision

The DAC variant's extended half-life produces sustained GH elevation that differs from natural pulsatile secretion. The no-DAC variant, used intermittently, more closely approximates physiological GH rhythms, which is one reason it is often preferred.

Medical supervision: A licensed healthcare provider assesses individual risk factors, monitors hormone levels, and adjusts care based on response. Avoid unregulated sources, which carry contamination, sterility, and dosing risks.

Frequently Asked Questions

What's the difference between CJC-1295 with DAC and without DAC?

The DAC (Drug Affinity Complex) modification allows the peptide to bind to albumin in the blood, extending its half-life from about 30 minutes to 6-8 days. This means the with-DAC version requires fewer injections but maintains elevated GH levels continuously, while the no-DAC version produces shorter GH pulses more similar to natural patterns.

Can I legally obtain CJC-1295 in the United States?

Not through compliant compounding pharmacies. CJC-1295 is currently Category 2 under FDA 503A guidelines, meaning it cannot be compounded by state-licensed pharmacies operating under federal oversight. Products from research chemical suppliers or international sources are not intended for human use and carry significant safety risks.

Why is CJC-1295 often paired with ipamorelin?

CJC-1295 (especially the no-DAC variant) and ipamorelin work through complementary mechanisms - GHRH receptors and ghrelin receptors, respectively. This combination is thought to produce more robust GH pulses than either peptide alone, potentially offering better results while maintaining more physiological secretion patterns. However, this combination is also not available through compliant compounding channels due to CJC-1295's Category 2 status.

Is CJC-1295 the same as Sermorelin?

No. While both are GHRH analogs that stimulate GH release, they have different structures and pharmacokinetics. Sermorelin is a 29-amino-acid peptide that corresponds to the active portion of natural GHRH and has a very short half-life. CJC-1295 incorporates amino acid substitutions and (in the DAC version) a binding modification that dramatically extends its duration of action. Importantly, Sermorelin is Category 1 and available for compounding, while CJC-1295 is Category 2 and not currently permitted.